HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.
Alexis
Frank
F
Department of Anesthesiology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis St., Boston, MA 02115, USA.
Basto
Pamela
P
Levy-Nissenbaum
Etgar
E
Radovic-Moreno
Aleksandar F
AF
Zhang
Liangfang
L
Pridgen
Eric
E
Wang
Andrew Z
AZ
Marein
Shawn L
SL
Westerhof
Katrina
K
Molnar
Linda K
LK
Farokhzad
Omid C
OC
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008301:Maleimides / Q000138:chemical synthesis / Q000737:chemistry; D053758:Nanoparticles / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000138:chemical synthesis / Q000737:chemistry; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013997:Time Factors; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D008301:Maleimides; D011092:Polyethylene Glycols; D018719:Erb-b2 Receptor Tyrosine Kinases; C043592:maleimide